Cardiovascular/Pulmonary: PBL Case 5

Konstantinides SV, Barco S, Lankeit M, Meyer G. Management of Pulmonary Embolism: An Update. J Am Coll Cardiol. 2016 Mar 1;67(8):976-90. doi:10.1016/j.jacc.2015.11.061.

Andexxa-An Antidote for Apixaban and Rivaroxaban. JAMA. 2018 Jul 24;320(4):399-400. doi: 10.1001/jama.2018.9257.

Ruopp NF, Cockrill BA. Diagnosis and Treatment of Pulmonary Arterial Hypertension: A Review. JAMA. 2022;327(14):1379-1391. doi:10.1001/jama.2022.4402

Detterbeck FC, Boffa DJ, Kim AW, Tanoue LT. The Eighth Edition Lung Cancer Stage Classification. Chest. 2017 Jan;151(1):193-203. doi: 10.1016/j.chest.2016.10.010.

Raval AN, Cigarroa JE, Chung MK, et al. Management of Patients on Non-Vitamin K Antagonist Oral Anticoagulants in the Acute Care and Periprocedural Setting: A Scientific Statement From the American Heart Association [published correction appears in Circulation. 2017 Mar 7;135(10 ):e647] [published correction appears in Circulation. 2017 Jun 13;135(24):e1144]. Circulation. 2017;135(10):e604-e633. doi:10.1161/CIR.0000000000000477

Hicks BM, Filion KB, Yin H, Sakr L, Udell JA, Azoulay L. Angiotensin converting enzyme inhibitors and risk of lung cancer: population based cohort study. BMJ. 2018;363:k4209. Published 2018 Oct 24. doi:10.1136/bmj.k4209

Kanaji N, Watanabe N, Kita N, Bandoh S, Tadokoro A, Ishii T, Dobashi H, Matsunaga T. Paraneoplastic syndromes associated with lung cancer. World J Clin Oncol. 2014 Aug 10;5(3):197-223. doi: 10.5306/wjco.v5.i3.197.